Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer

Journal of Surgical Oncology

Volumn 107, Issue 5, 2013, Pages 550-554

  Xi, Ren Chong ^a   Sheng, Yin Rui ^a   Chen, Wang Hong ^a   Sheng, Li ^a   Gang, Ji Jing ^a   Tong, Zhou ^a   Shan, Zhang ^a   Ying, Guo Hong ^a   Dong, Liu Chun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

non muscle invasive bladder cancer; recurrence; survivin and livin

Indexed keywords

LIVIN; SURVIVIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; TRANSURETHRAL RESECTION; UROTHELIUM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REGRESSION ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84875233442     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23272     Document Type: Article

References (30)

1. Youssef RF, Lotan Y,: Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. Scientific World Journal 2011; 11: 369-381.
2. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
3. Shariat SF, Karam JA, Lerner SP,: Molecular markers in bladder cancer. Curr Opin Urol 2008; 18: 1-8.
4. Karam JA, Lotan Y, Karakiewicz PI, et al.: Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-136.
5. Margulis V, Lotan Y, Montorsi F, et al.: Predicting survival after radical cystectomy for bladder cancer. BJU Int 2008; 102: 15-22.
6. Ren Chong Xi, Wang Shou Biao, Zhang Zhi Gang,: Elevation of survivin and livin expression in human colorectal cancer: Inverse correlation between expression and overall survival. Onkologie 2011; 34: 428-432.
7. Mostofi FK, Sobin LH, Torloni H,: International histological classification of tumors. No. 10. histological typing of urinary bladder tumors. Geneva, Switzerland: World Health Organization; 1973.
8. Sobin LH, Gospodariwicz M, Wittekind C,: editors. TNM classification of malignant tumors. UICC international union against cancer, 7th edition. Germany: Wiley-Blackwell; 2009.
9. Chu XY, Chen LB, Wang JH, et al.: Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. Surg Oncol 2012; 105: 520-528.
10. Eissa S, Kassim S, EI-Almady O,: Detection of bladder tumours role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003; 15: 395-403.
11. Shinka T, Ogura H, Morita T, et al.: Relationship between glutathione S-transferase M1 deficiency and urothelial cancer in dye workers exposed to aromatic amine. J Urol 1998; 159: 380-383.
12. Chang Hong, Shimmer AaronD,: Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 2007; 6: 24-30.
13. Liu B, Han M, Wen JK, et al.: Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 2007; 250: 168-176.
14. Gazzaniga P, Gradilone A, Giuliani L,: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the Progression of superficial bladder cancer. Ann Oncol 2003; 14: 85-89.
15. Liu HB, Kong CZ, Zeng Y, et al.: Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment. Urol Oncol 2009; 27: 277-283.
16. Li F, Ling X,: Survivin study: An update of "what is the next wave "? J Cell Physiol 2006; 208: 476-486.
17. Swana HS, Grossman D, Anthony JN, et al.: Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-453.
18. Li F,: Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-216.
19. Nakanishi K, Tominaga S, Hiroi S, et al.: Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 2002; 441: 559-563.
20. Ku JH, Kwak C, Lee HS, et al.: Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004; 171: 631-635.
21. Lehner R, Lucia MS, Jarboe EA, et al.: Immunohistochemical localizationof the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002; 10: 134-138.
22. Gazzaniga P, Gradilone A, Giuliani L, et al.: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003; 14: 85-90.
23. Yin W, Chen N, Zhang Y, et al.: Survivin nuclear labeling index: A superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 2006; 19: 1487-1497.
24. Schultz IJ, Wester K, Straatman H, et al.: Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007; 51: 416-423.
25. Smith SD, Wheeler MA, Plescia J, et al.: Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-328.
26. Shariat SF, Casella R, Khoddami SM, et al.: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004; 171: 626-630.
27. Weikert S, Christoph F, Schrader M, et al.: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005; 116: 100-104.
28. Wang H, Xi X, Kong X, et al.: The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 2004; 130: 487-490.
29. Schultz IJ, Wester K, Straatman H, et al.: Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007; 51: 416-422.
30. Karam JA, Lotan Y, Ashfaq R, et al.: Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007; 70: 482-486.